Charles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Charles Schwab Investment Management Inc. grew its position in Replimune Group, Inc. (NASDAQ:REPL) by 12.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 484,797 shares of the company’s stock after acquiring an additional 52,498 shares during the period. Charles Schwab Investment Management Inc. owned 0.71% of Replimune Group worth $5,313,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the stock. Nisa Investment Advisors LLC grew its holdings in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the period. Bank of New York Mellon Corp grew its holdings in Replimune Group by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after acquiring an additional 17,471 shares during the period. Rhumbline Advisers grew its holdings in Replimune Group by 7.2% during the 2nd quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after acquiring an additional 5,732 shares during the period. TD Asset Management Inc grew its holdings in Replimune Group by 4.6% during the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock worth $2,249,000 after acquiring an additional 11,094 shares during the period. Finally, Arizona State Retirement System acquired a new stake in Replimune Group during the 2nd quarter worth about $108,000. 92.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the company. Jefferies Financial Group raised their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm initiated coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. BMO Capital Markets lifted their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Trading Down 3.3 %

Shares of REPL stock opened at $12.22 on Friday. The company’s fifty day simple moving average is $12.17 and its two-hundred day simple moving average is $10.40. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market capitalization of $836.06 million, a price-to-earnings ratio of -4.01 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, analysts anticipate that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is owned by company insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.